Literature DB >> 25973003

miR-205 regulates A549 cells proliferation by targeting PTEN.

Jinghui Bai1, Xiangyu Zhu1, Jianqi Ma1, Wanting Wang1.   

Abstract

miR-205 is an epithelial-specific miRNA and has been shown to orchestrate some cellular processes such as epithelial mesenchymal transition (EMT) and differentiation fate of stem cells in mammary gland. miR-205 play a part of a tumor suppressor in human cancers. However, the role of miR-205 in lung cancer is unclear. In this study, we detected the expression level of miR-205 in 46 cases clinical lung cancer specimens and adjacent normal tissues by stem-loop RT-PCR. We found that the expression of miR-205 was significantly increased in lung cancer specimens compared to adjacent normal tissues (P < 0.01). Furthermore, we observed the expressions of PTEN protein and mRNA in lung cancer tissues and adjacent normal tissues by methods of western blot and Real time PCR respectively. We found that the expressions of PTEN protein and mRNA was significantly decreased in lung cancer specimens compared to adjacent normal tissues. And then, we found there is a negative relationship between the expression of miR-205 and PTEN mRNA in lung cancer by analyzed. To validate whether PTEN was direct targets of miR-205, a dual-luciferase reporter assay was employed, the result showed that PTEN is a target gene of MiR-205. In subsequent experiments, we examined the expressions of PTEN protein and mRNA after transfection of miR-205 mimics or inhibitor into A549 cells, and A549 cell proliferation was measured by CCK-8 tests. We found that the expression of PTEN protein and mRNA in A549 cells were significantly down-regulated or up-regulated after miR-205 mimics and miR-205 inhibitors transfected into, and miR-205 could inhibits A549 cells proliferation. These results indicate that miR-205 might inhibitor the proliferation of A549 cells by regulating the expression of PTEN.

Entities:  

Keywords:  Lung cancer; PTEN; miR-205; proliferation

Mesh:

Substances:

Year:  2015        PMID: 25973003      PMCID: PMC4396313     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  22 in total

1.  PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration.

Authors:  Carmen J Marsit; Shichun Zheng; Kenneth Aldape; Philip W Hinds; Heather H Nelson; John K Wiencke; Karl T Kelsey
Journal:  Hum Pathol       Date:  2005-07       Impact factor: 3.466

Review 2.  MiR-205 in cancer: an angel or a devil?

Authors:  Ai-Ying Qin; Xin-Wei Zhang; Liang Liu; Jin-Pu Yu; Hui Li; Shi-Zhen Emily Wang; Xiu-Bao Ren; Shui Cao
Journal:  Eur J Cell Biol       Date:  2012-12-29       Impact factor: 4.492

3.  Expression analysis of MiR-21, MiR-205, and MiR-342 in breast cancer in Iran.

Authors:  Shahram Savad; Parvin Mehdipour; Mohammad Miryounesi; Reza Shirkoohi; Forouzandeh Fereidooni; Fatemeh Mansouri; Mohammad Hossein Modarressi
Journal:  Asian Pac J Cancer Prev       Date:  2012

4.  Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.

Authors:  Chizuko Yamamoto; Yuji Basaki; Akihiko Kawahara; Kazutaka Nakashima; Masayoshi Kage; Hiroto Izumi; Kimitoshi Kohno; Hidetaka Uramoto; Kosei Yasumoto; Michihiko Kuwano; Mayumi Ono
Journal:  Cancer Res       Date:  2010-10-19       Impact factor: 12.701

5.  Screening of microRNA in patients with esophageal cancer at same tumor node metastasis stage with different prognoses.

Authors:  Bao-Sheng Zhao; Shang-Guo Liu; Tian-Yun Wang; Ying-Hua Ji; Bo Qi; Yi-Peng Tao; Han-Chen Li; Xiang-Nan Wu
Journal:  Asian Pac J Cancer Prev       Date:  2013

6.  Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.

Authors:  Naoki Yanagawa; Charles Leduc; Derek Kohler; Mauro A Saieg; Thomas John; Jenna Sykes; Maisa Yoshimoto; Melania Pintilie; Jeremy Squire; Frances A Shepherd; Ming-Sound Tsao
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

Review 7.  MicroRNAs as regulators of epithelial-mesenchymal transition.

Authors:  Philip A Gregory; Cameron P Bracken; Andrew G Bert; Gregory J Goodall
Journal:  Cell Cycle       Date:  2008-10-25       Impact factor: 4.534

8.  Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer.

Authors:  Lorenzo F Sempere; Mette Christensen; Asli Silahtaroglu; Mads Bak; Catherine V Heath; Gary Schwartz; Wendy Wells; Sakari Kauppinen; Charles N Cole
Journal:  Cancer Res       Date:  2007-12-15       Impact factor: 12.701

9.  PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer.

Authors:  W T Lim; W H Zhang; C R Miller; J W Watters; F Gao; A Viswanathan; R Govindan; H L McLeod
Journal:  Oncol Rep       Date:  2007-04       Impact factor: 3.906

10.  MiR-133b regulates bladder cancer cell proliferation and apoptosis by targeting Bcl-w and Akt1.

Authors:  Xiao-Nan Chen; Ke-Feng Wang; Zhen-Qun Xu; Shi-Jie Li; Qiang Liu; Dong-Hui Fu; Xia Wang; Bin Wu
Journal:  Cancer Cell Int       Date:  2014-07-19       Impact factor: 5.722

View more
  18 in total

1.  LncRNA ADPGK-AS1 promotes pancreatic cancer progression through activating ZEB1-mediated epithelial-mesenchymal transition.

Authors:  Suzhen Song; Weihua Yu; Sen Lin; Mingbao Zhang; Teng Wang; Shuang Guo; Hongbo Wang
Journal:  Cancer Biol Ther       Date:  2018-04-19       Impact factor: 4.742

2.  Analysis of key genes and micro-RNA-mRNA regulatory networks in women with ulcerative interstitial cystitis/pain bladder syndrome.

Authors:  Shengzhuo Liu; Shijian Feng; Deyi Luo
Journal:  Int Urogynecol J       Date:  2018-11-19       Impact factor: 2.894

3.  MicroRNA-205 is downregulated in hepatocellular carcinoma and inhibits cell growth and metastasis via directly targeting vascular endothelial growth factor A.

Authors:  Xuya Zhao; Shi Zhou; Dazhi Wang; Wei He; Junxiang Li; Shuai Zhang
Journal:  Oncol Lett       Date:  2018-06-08       Impact factor: 2.967

4.  MicroRNA-205-5p regulates the chemotherapeutic resistance of hepatocellular carcinoma cells by targeting PTEN/JNK/ANXA3 pathway.

Authors:  Ping Shao; Wei-Kun Qu; Cheng-Ye Wang; Yu Tian; Ming-Liang Ye; De-Guang Sun; Ji-Dong Sui; Li-Ming Wang; Rong Fan; Zhen-Ming Gao
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

5.  Novel MicroRNA signatures in HPV-mediated cervical carcinogenesis in Indian women.

Authors:  Shweta Sharma; Showket Hussain; Kartik Soni; Pallavi Singhal; Richa Tripathi; V G Ramachandran; Sonal Sharma; Shukla Das; Beena Pillai; Mausumi Bharadwaj
Journal:  Tumour Biol       Date:  2015-10-27

6.  Inhibition Sequence of miR-205 Hinders the Cell Proliferation and Migration of Lung Cancer Cells by Regulating PETN-Mediated PI3K/AKT Signal Pathway.

Authors:  Huizhen Zhu; Yan Xu; Meng Li; Zhitao Chen
Journal:  Mol Biotechnol       Date:  2021-03-30       Impact factor: 2.695

7.  Expression of miR-590 in lung cancer and its correlation with prognosis.

Authors:  Zhifeng Ma; Yaoqin Wang; Binjun He; Jian Cui; Chu Zhang; Haiyong Wang; Weizhong Feng; Bin Wang; Desheng Wei; Yuanlin Wu; Yong Zeng; Guangmao Yu
Journal:  Oncol Lett       Date:  2017-11-28       Impact factor: 2.967

8.  MiR-205 as a promising biomarker in the diagnosis and prognosis of lung cancer.

Authors:  Jing-Hua Li; Shan-Shan Sun; Ning Li; Peng Lv; Shu-Yang Xie; Ping-Yu Wang
Journal:  Oncotarget       Date:  2017-08-14

9.  TGF-β1 regulating miR-205/miR-195 expression affects the TGF-β signal pathway by respectively targeting SMAD2/SMAD7.

Authors:  Yingjun Duan; Qianxue Chen
Journal:  Oncol Rep       Date:  2016-08-17       Impact factor: 3.906

10.  Integrated analysis of microRNA regulatory network in nasopharyngeal carcinoma with deep sequencing.

Authors:  Fan Wang; Juan Lu; Xiaohong Peng; Jie Wang; Xiong Liu; Xiaomei Chen; Yiqi Jiang; Xiangping Li; Bao Zhang
Journal:  J Exp Clin Cancer Res       Date:  2016-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.